Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Express Scripts
Dow
Mallinckrodt
Moodys

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

DRIZALMA SPRINKLE Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Drizalma Sprinkle patents expire, and when can generic versions of Drizalma Sprinkle launch?

Drizalma Sprinkle is a drug marketed by Sun Pharma Global and is included in one NDA. There is one patent protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in DRIZALMA SPRINKLE is duloxetine hydrochloride. There are forty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the duloxetine hydrochloride profile page.

Summary for DRIZALMA SPRINKLE
International Patents:1
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Formulation / Manufacturing:see details
DailyMed Link:DRIZALMA SPRINKLE at DailyMed
Drug patent expirations by year for DRIZALMA SPRINKLE

US Patents and Regulatory Information for DRIZALMA SPRINKLE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharma Global DRIZALMA SPRINKLE duloxetine hydrochloride CAPSULE, DELAYED RELEASE;ORAL 212516-001 Jul 19, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sun Pharma Global DRIZALMA SPRINKLE duloxetine hydrochloride CAPSULE, DELAYED RELEASE;ORAL 212516-004 Jul 19, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Sun Pharma Global DRIZALMA SPRINKLE duloxetine hydrochloride CAPSULE, DELAYED RELEASE;ORAL 212516-002 Jul 19, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sun Pharma Global DRIZALMA SPRINKLE duloxetine hydrochloride CAPSULE, DELAYED RELEASE;ORAL 212516-003 Jul 19, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for DRIZALMA SPRINKLE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0273658 2005C/001 Belgium   Start Trial PRODUCT NAME: CHLORHYDRATE DE DULOXETINE; REGISTRATION NO/DATE: EU/1/04/280/001 20040811
0273658 C300171 Netherlands   Start Trial PRODUCT NAME: DULOXETINE EN FARMACEUTISCH AANVAARDBARE ZUURADDITIEZOUTEN DAARVAN, EN IN HET BIJZONDER DULOXETINE HYDROCHLORIDE; NATL REGISTRATION NO/DATE: EU/1/04/280/001-006 20040811
0273658 SPC/GB05/003 United Kingdom   Start Trial PRODUCT NAME: DULOXETINE AND PHARMACUETICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, AND IN PARTICULAR DULOXETINE HYDROCHLORIDE; REGISTERED: UK EU/1/04/280/001 20040811; UK EU/1/04/280/002 20040811; UK EU/1/04/280/003 20040811; UK EU/1/04/280/004 20040811; UK EU/1/04/280/005 20040811; UK EU/1/04/280/006 20040811
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Dow
Harvard Business School
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.